Bone Marrow Stromal Stem Cells in Tissue Engineering and Regenerative Medicine.

Bone Marrow Stromal Stem Cells in Tissue Engineering and Regenerative Medicine.
复制标题

DOI:
10.1055/s-0042-118458
复制
发表时间:
2016-11
影响因子:
2.2
通讯作者:
Kaigler, D.
Kaigler, D.
中科院分区:
医学4区
文献类型:
--
作者:
Polymeri, A.;Giannobile, W. V.;Kaigler, D.

文献摘要

参考文献

被引文献

相似文献

骨髓基质干细胞(BMSCs)是成体多能细胞,其具有分化为中胚层来源的细胞类型,即骨细胞、脂肪细胞和软骨细胞的潜能。由于其可及性和扩增潜力,BMSCs在组织工程和再生医学应用中具有历史性的治疗前景。最近,已经证明骨髓基质干细胞不仅可以直接参与组织再生,而且它们还具有迁移到组织损伤的远端部位的能力,在那里它们可以直接通过其分化或间接通过旁分泌机制参与组织修复。此外,它们可以引发各种免疫调节信号,这可以减弱炎症和免疫反应。因此,骨髓基质干细胞已在临床上被探索用于治疗各种各样的不同病症,包括骨缺损、移植物抗肿瘤、骨缺损宿主疾病、心血管疾病、自身免疫性疾病、糖尿病、神经系统疾病和肝肾疾病。本文综述了目前骨髓基质干细胞的临床应用,并讨论了其治疗特性,同时也解决了其使用的局限性。使用几个关键词检索PubMed、奥维德和Google Scholar在线数据库,包括“干细胞”、“组织工程”、“组织再生”和“临床试验”。此外,Clinicaltrials.gov用于查找使用骨髓衍生干细胞的已完成临床试验。
Bone marrow stromal stem cells (BMSCs) are adult multipotent cells, which have the potential to differentiate into cell types of mesodermal origin, namely osteocytes, adipocytes, and chondrocytes. Due to their accessibility and expansion potential, BMSCs have historically held therapeutic promise in tissue engineering and regenerative medicine applications. More recently, it has been demonstrated that not only can bone marrow stromal stem cells directly participate in tissue regeneration, but they also have the capacity to migrate to distant sites of tissue injury, where they can participate in tissue repair either directly through their differentiation or indirectly through paracrine mechanisms. Additionally, they can elicit various immunomodulatory signals, which can attenuate the inflammatory and immune responses. As such, bone marrow stromal stem cells have been explored clinically for treatment of a wide variety of different conditions including bone defects, graft-vs.-host disease, cardiovascular diseases, autoimmune diseases, diabetes, neurological diseases, and liver and kidney diseases. This review provides an overview of current clinical applications of bone marrow stromal stem cells and discusses their therapeutic properties, while also addressing limitations of their use. PubMed, Ovid, and Google Scholar online databases were searched using several keywords, including “stem cells”, “tissue engineering”, tissue regeneration” and “clinical trials”. Additionally, Clinicaltrials.gov was used to locate completed clinical trials using bone marrow derived stem cells.
DOI: 10.1016/s1474-4422(11)70305-2
发表时间: 2012-02
期刊: LANCET NEUROLOGY
影响因子: 48
作者:
Connick, Peter;Kolappan, Madhan;Crawley, Charles;Webber, Daniel J.;Patani, Rickie;Michell, Andrew W.;Du, Ming-Qing;Luan, Shi-Lu;Altmann, Daniel R.;Thompson, Alan J.;Compston, Alastair;Scott, Michael A.;Miller, David H.;Chandran, Siddharthan
通讯作者: Chandran, Siddharthan
DOI: 10.1016/j.jacc.2009.06.055
发表时间: 2009-12-08
影响因子: 24
作者:
Hare, Joshua M.;Traverse, Jay H.;Henry, Timothy D.;Dib, Nabil;Strumpf, Robert K.;Schulman, Steven P.;Gerstenblith, Gary;DeMaria, Anthony N.;Denktas, Ali E.;Gammon, Roger S.;Hermiller, James B., Jr.;Reisman, Mark A.;Schaer, Gary L.;Sherman, Warren
通讯作者: Sherman, Warren
DOI: 10.3109/14653249.2011.574118
发表时间: 2011-01-01
期刊: CYTOTHERAPY
影响因子: 4.5
作者:
Chin, Sze-Piaw;Poey, Alfred C.;Cheong, Soon-Keng
通讯作者: Cheong, Soon-Keng
DOI: 10.1055/s-0033-1363989
发表时间: 2014-05-01
影响因子: 2.2
作者:
Dumic-Cule, I.;Draca, N.;Vukicevic, S.
通讯作者: Vukicevic, S.
DOI: 10.1186/1479-5876-11-21
发表时间: 2013-01-26
影响因子: 7.4
作者:
Chen G;Wang Y;Xu Z;Fang F;Xu R;Wang Y;Hu X;Fan L;Liu H
通讯作者: Liu H